 |
|
La Jolla Institute unlocks mystery of potentially fatal reaction to smallpox vaccine
May 26, 2009Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine. The research, conducted in mouse models, was funded under a special research network created by the National Institutes of Health in 2004. The network is working toward the development of a new smallpox vaccine that could be administered to the millions of Americans who suffer from atopic dermatitis, a chronic, itchy skin condition commonly referred to as eczema.
The La Jolla Institute's Toshiaki and Yuko Kawakami, M.D.s, Ph.D.s., a husband and wife scientific team, led the research group which found that activity levels of Natural Killer (NK) cells played a pivotal role in the development of eczema vaccinatum in the mice. The activity of the NK cells, which are disease fighting cells of the immune system, was significantly lower in the mice that developed eczema vaccinatum than in normal mice that also received the smallpox vaccine. This knowledge opens the door to one day developing therapies that could potentially boost NK cell activity in eczema sufferers.
"Since atopic dermatitis affects as many as 17 percent of children in the U. S. and since eczema vaccinatum carries a fatality rate of 5-10 percent, therapies that prevent or treat eczema vaccinatum successfully are crucial should the need for mass vaccination against smallpox arise in response to bioterrorism," said Harvard pediatrics professor Raif S. Geha, M.D., chief of immunology at Boston Children's Hospital and a principal investigator in the NIH funded network investigating eczema vaccinatum. "The discovery of the Kawakami team, who are participants in the NIH network, is an important step towards this goal."
People with active atopic dermatitis (eczema), or who have outgrown atopic dermatitis, and the people they live with currently cannot receive smallpox vaccinations because of the risk of eczema vaccinatum. While uncommon, eczema vaccinatum can develop when atopic dermatitis patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. It is estimated that a significant portion of the U.S. population is currently not eligible for smallpox vaccination.
"This discovery answers an important question that has long eluded the scientific community, "why people with atopic dermatitis were susceptible to developing eczema vaccinatum upon receiving the smallpox vaccine, while the general population was not," said Mitchell Kronenberg, the La Jolla Institute's president & scientific director. "It marks a significant advance toward the goal of ensuring that everyone can one day be protected against the smallpox virus."
The finding was published today in the online version of the Journal of Experimental Medicine in a paper entitled, "Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum." La Jolla Institute scientist Shane Crotty, Ph.D., also contributed to the study.
Regarded as the deadliest disease ever known to man, smallpox was officially eradicated worldwide in 1980 and routine vaccinations against the disease ended in the U.S in 1972. However, bioterrorism concerns have arisen over recent years regarding the deliberate distribution of the smallpox virus, which might make smallpox vaccinations once again necessary. Such concerns led to the creation of the Atopic Dermatitis and Vaccinia Network (ADVN), a consortium of medical and research institutions nationwide developed by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The network, which provided grant funding for the Kawakami's studies under NIH contact N01-AI40030C, was launched in 2004 with the goal of developing a new smallpox vaccine that would be safe for atopic dermatitis sufferers. It includes three consortiums, involving data, clinical testing and animal studies, of which Drs. Kawakami and the La Jolla Institute are members.
The Animal Studies Consortium was created to establish animal models of atopic dermatitis and investigate their immune responses to vaccinia - the virus used in smallpox vaccine. Drs. Kawakami were invited to join the consortium due to their creation of a new, more effective atopic dermatitis mouse model in 2004.
In their study, Drs. Kawakami showed that eczema-infected mice had higher levels of IL-17 cells, which are known to inhibit NK cell activity. "This higher level of IL-17 cells slowed down the ability of the NK cells to kill the vaccinia virus," said Yuko Kawakami, noting people with atopic dermatitis are also known to have higher numbers of IL-17 producing cells. "This led to the development of eczema vaccinatum when these mice received the smallpox vaccine."
Drs. Kawakami tested their theory by stimulating more NK cell activity in the eczema-infected mice. The higher activity led to the elimination of the eczema vaccinatum infection. "We are very excited by these findings, " said Toshiaki Kawakami. "Developing a safer smallpox vaccine is the most important thing in this field."
La Jolla Institute for Allergy and Immunology
People with active atopic dermatitis (eczema), or who have outgrown atopic dermatitis, and the people they live with currently cannot receive smallpox vaccinations because of the risk of eczema vaccinatum. While uncommon, eczema vaccinatum can develop when atopic dermatitis patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. It is estimated that a significant portion of the U.S. population is currently not eligible for smallpox vaccination.
"This discovery answers an important question that has long eluded the scientific community, "why people with atopic dermatitis were susceptible to developing eczema vaccinatum upon receiving the smallpox vaccine, while the general population was not," said Mitchell Kronenberg, the La Jolla Institute's president & scientific director. "It marks a significant advance toward the goal of ensuring that everyone can one day be protected against the smallpox virus."
The finding was published today in the online version of the Journal of Experimental Medicine in a paper entitled, "Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum." La Jolla Institute scientist Shane Crotty, Ph.D., also contributed to the study.
Regarded as the deadliest disease ever known to man, smallpox was officially eradicated worldwide in 1980 and routine vaccinations against the disease ended in the U.S in 1972. However, bioterrorism concerns have arisen over recent years regarding the deliberate distribution of the smallpox virus, which might make smallpox vaccinations once again necessary. Such concerns led to the creation of the Atopic Dermatitis and Vaccinia Network (ADVN), a consortium of medical and research institutions nationwide developed by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The network, which provided grant funding for the Kawakami's studies under NIH contact N01-AI40030C, was launched in 2004 with the goal of developing a new smallpox vaccine that would be safe for atopic dermatitis sufferers. It includes three consortiums, involving data, clinical testing and animal studies, of which Drs. Kawakami and the La Jolla Institute are members.
The Animal Studies Consortium was created to establish animal models of atopic dermatitis and investigate their immune responses to vaccinia - the virus used in smallpox vaccine. Drs. Kawakami were invited to join the consortium due to their creation of a new, more effective atopic dermatitis mouse model in 2004.
In their study, Drs. Kawakami showed that eczema-infected mice had higher levels of IL-17 cells, which are known to inhibit NK cell activity. "This higher level of IL-17 cells slowed down the ability of the NK cells to kill the vaccinia virus," said Yuko Kawakami, noting people with atopic dermatitis are also known to have higher numbers of IL-17 producing cells. "This led to the development of eczema vaccinatum when these mice received the smallpox vaccine."
Drs. Kawakami tested their theory by stimulating more NK cell activity in the eczema-infected mice. The higher activity led to the elimination of the eczema vaccinatum infection. "We are very excited by these findings, " said Toshiaki Kawakami. "Developing a safer smallpox vaccine is the most important thing in this field."
La Jolla Institute for Allergy and Immunology
Eczema Current Events and Eczema News RSSLatest analysis confirms suboptimal vitamin D levels in millions of US children
Millions of children in the United States between the ages of 1 and 11 may suffer from suboptimal levels of vitamin D, according to a large nationally representative study published in the November issue of Pediatrics, accompanied by an editorial.
Preventing allergies
Allergic diseases are becoming increasingly common in Western industrialized countries. As there is still no etiologically based treatment of allergic asthma, hay fever, or atopic eczema, the prevention of these diseases is a matter of special importance.
Gut worms may protect against house-dust mite allergy
A study conducted in Vietnam has added further weight to the view that parasitic gut worms, such as hookworm, could help in the prevention and treatment of asthma and other allergies.
Scientists identify genetic cause of previously undefined primary immune deficiency disease
Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency.
Allergies among youth on the rise
Asthma, nasal symptoms and eczema is a major public health problem in Sweden, not least among young people. Half of all teenagers are affected in Västra Götaland County in West Sweden.
Study Characterizes Eczema Patients Most at Risk for Dangerous Viral Infections
Eczema patients at risk for serious viral infections have more severe disease, are more likely to be allergic to food and other allergens, and have a frequent history of staph infections.
Promising antimicrobial attacks virus, stimulates immune system
A promising antimicrobial agent already known to kill bacteria can also kill viruses and stimulate the innate immune system, according to researchers at National Jewish Health.
Study finds unexpected bacterial diversity on human skin
The health of our skin - one of the body's first lines of defense against illness and injury - depends upon the delicate balance between our own cells and the millions of bacteria and other one-celled microbes that live on its surface.
New data analysis shows possible link between childhood obesity and allergies
A new study indicates there may be yet another reason to reduce childhood obesity - it may help prevent allergies. The study published in the May issue of the Journal of Allergy and Clinical Immunology showed that obese children and adolescents are at increased risk of having some kind of allergy, especially to a food.
Sublingual immunotherapy for inhalant allergies deserves deeper consideration
Sublingual immunotherapy for the treatment of allergy symptoms caused by a wide variety of environmental inhalants has been effectively used in Europe.
More Eczema Current Events and Eczema News Articles
 |
Loma Lux Homeopathic Medicine, Eczema, 100 Tablet Bottle by Loma Lux For relief from dry skin, itching, rashes, Eczema and Atopic Dermatitis. Dermatologist Steven A. Smith, MD, developed the Loma Lux Eczema formula and has proven its effectiveness in treating his patients. Get relief from the symptoms of dry, itching skin and rashes with Loma Lux Eczema. Loma Lux is dedicated to promoting worldwide health and wholeness through the use of natural, low dose, low side effect treatments, bringing freedom from chronic diseases. |
 |
Healing Eczema: Nutrition, Detoxification, Anti-Stress Coping Skills And External Practices To Heal Eczema by Christina Nevada (Author) Written from the feedback of thousands of eczema sufferers worldwide by a 20-year naturopathic dermatology eczema researcher and former eczema sufferer, this book is essential for both physicians and patients. |
 |
Adovia Natural Dead Sea Mud Soap - Great for Eczema, Psoriasis or Acne! by Adovia Mineral Skin Care Our All Natural Black Mud Soap contains a unique combination of Dead Sea minerals derived from Dead Sea Mud. This effective mud soap removes dirt and cleanses your skin, while simultaneously infusing it with minerals essential to keeping your skin hydrated and moisturized. Our Dead Sea mud soap is enriched with century old Dead Sea mud, leaving your skin cleansed and nourished. As more people are learning about the healing and beauty effects of black mud from The Dead Sea, this soap is becoming a very popular choice for skin care conscious people. |
 |
Eczema-Free for Life by Adnan Nasir (Author), Priscilla Burgess (Author) Rid yourself of eczema forever! Based on new research, this book has everything the millions of eczema sufferers need to know to free themselves from unbearable itching and unsightly rashes. Eczema–Free For Life contains the latest medical information about the cause, symptoms, and treatments of eczema and is written both for adults with eczema and the parents of children with eczema. In addition to the most recent medical research, Dr. Nasir offers guidance for home care and ways to cope with the psychological impact of the disorder. None of the popular books about eczema currently on the market is written by a practicing dermatologist and none is based on up–to–date science. New research has conclusively demonstrated that eczema is the result of the abnormal development... |
 |
Dermarest Eczema Medicated Lotion 4 fl oz (118 ml) by Insight Pharmaceuticals Now! 24-hour Itch Relief of Dry, Itchy Skin 1% Hydrocortisone offers |
 |
AmLactin XL Cream, 5.6 Ounces by AmLactin AmLactin XL Moisturizing Lotion contains Ultraplex formulation, a proprietary blend of alpha-hydroxy moisturizing compounds. AmLactin Cream is a special formulation of 12% lactic acid, neutralized with ammonium hydroxide, to form ammonium lactate that provides a cream pH of 4.5 - 5.5. Lactic acid, an alpha-hydroxy acid, has been reported as an effective, naturally-occurring humectant in the skin. It has beneficial effects on dry, scaly skin and itching associated with this condition |
 |
The Skin Cure Diet: Heal Eczema from Inside Out by Kathleen Waterford (Author) It’s a short, simple, drastically different diet—not necessarily easy, but simple and effective. The goal of this guide is to help people with eczema or almost any kind of skin disorder heal themselves without ongoing dependence on drugs, creams, lotions, or other medicine by relating what worked for this author personally to cure her eczema, dermatitis and acne. There’s a lot of information out there, especially on the internet, but much of it can seem vague or conflicting regarding the combination of symptoms you may have. Waterford did a lot of informal research and trial and error over a long period of time and eventually cured her eczema, general health, and most of her allergies with a natural diet. If you’ve had no luck with doctors, allergy drugs, cortisone cream, or other... |
 |
Eczema No More - 11 ML., (Forces Of Nature) by Forces of Nature Medically Proven to eliminate eczema - results guaranteed Approved for over the counter sales and safe for use Doctor recommended and proven effective 100% Pure, all Natural, with Certified Organic ingredients Eczema No More is a100% pure and all natural with Certified Organic ingredients. This treatment is a blend of Certified Organic essential oils and plant extracts which are proven in published medical studies to eliminate eczema. Eczema is a common skin condition that can be controlled in nearly every patient by using Eczema No More. Results guaranteed. The 100% pure and natural extracts and essential oils in this product are of the purest quality and proven to quickly provide relief from eczema infections and restore hygiene. The all natural agents in Eczema No More act by healing... |
 |
Egyptian Magic Cream 4 Oz by Egyptian Magic It doesnt clog pores, adds an amazing glow and hydrates body, face and hair, perfect after-shaving lotion, softens hands and feet, super lip and eye gloss, great hot-oil treatment for hair - hair will be shine, daily hair conditioner, heals chapped lips, eases irritation from mosquito bites, treats burns, and blemishes, great for eczema, diaper rashes, pregnant woman love it to keep their expanding belly moisturized, great prep for use on skin pre-surgery and post-surgery, and on, and on... Youll save time, money, energy and space in your shower, purse, or suitcase. As Seen In: Vogue, Allure, Daily Candy, Lucky, Shape, People Ingredients: Olive Oil, BeesWax,Honey Bee Pollen, Royal Jelly, Bee Propolis and Love. It doesnt clog pores, adds an amazing glow and hydrates body, face... |
 |
The Natural Way With Eczema/a Comprehensive Guide to Gentle, Safe and Effective Treatment by Sheena Meredith (Author), Richard Thomas (Editor) |
| © 2009 BrightSurf.com |